NCT02217332 - Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 14, 2016

Study Completion Date

January 20, 2017

Conditions

Chronic Sinusitis With Nasal Polyps and Eosinophilia

Interventions

DRUG

dexpramipexole

Dexpramipexole capsule-shaped film-coated tablets at the dose strength of 150 mg administered orally as 1 tablet twice daily (300 mg/day)

Trial Locations (7)

University of Pittsburgh School of Medicine, Pittsburgh

University of Pennsylvania, Philadelphia

Johns Hopkins University, Baltimore

University of Virginia, Charlottesville

Wake Research Associates, Raleigh

ENT Associates of South Florida, Boca Raton

Brigham and Women's Hospital, Boston